Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.

Kūlaris improved quality of life for acne sufferers without side effects.

Clascoterone cream is a safer, effective acne treatment with fewer side effects.

Baricitinib effectively treated alopecia areata in 73% of patients, with minor metabolic changes and significant changes in inflammatory markers.

Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Baricitinib is effective for severe alopecia areata but has some side effects.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Clascoterone cream 1% is effective and well-tolerated for treating acne and other related conditions.

The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.

The new cream with N-acetyl glucosamine didn't change skin color after 8 weeks.

Latanoprost, a glaucoma medication, caused excessive eyelid hair growth in many patients.

Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.

Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.

HAC and BAC improve skin targeting and reduce diffusion without causing irritation.

Bimatoprost is safe but not effective for severe eyelash loss from alopecia areata, possibly helping those with less loss.

Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Latanoprost and minoxidil effectively control hair loss and increase hair count.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.

Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.

Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.